Skip to main content
Zarife Sahenk, MD, Neurology, Columbus, OH

ZarifeSahenkMD

Neurology Columbus, OH

Neuromuscular Medicine

Professor of Pediatrics, Ohio State University

Dr. Sahenk is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sahenk's full profile

Already have an account?

  • Office

    555 S 18th St
    Columbus, OH 43205
    Phone+1 614-722-6200
    Fax+1 614-722-3273

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalResidency, Neurology, 1975 - 1978
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 1974 - 1975
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Physical Medicine and Rehabilitation, 1972 - 1974
  • Hacettepe University FOM
    Hacettepe University FOMClass of 1972

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1978 - 2026
  • IL State Medical License
    IL State Medical License 1977 - 1984
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular Dystrophy  
    Jerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy, Richard Shell, JAMA Neurology

Authored Content

  • Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular DystrophyJune 2020

Press Mentions

  • Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
    Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2ASeptember 3rd, 2021
  • First Global CMT Research Convention Planned for September
    First Global CMT Research Convention Planned for SeptemberJune 16th, 2021
  • Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to Its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy
    Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to Its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular DystrophyMay 8th, 2019
  • Join now to see all

Grant Support

  • NT-3 Gene Therapy To Improve Peripheral Nerve Function Induced By Genetic DefectNational Institute Of Neurological Disorders And Stroke2010–2011
  • Histopathology CoreEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2011
  • Histopathology CoreNational Institute Of Neurological Disorders And Stroke2007–2010

Professional Memberships